NO-donor thiacarbocyanines as multifunctional agents for Alzheimer's disease.

[1]  S. Lipton,et al.  Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[2]  D. Puzzo,et al.  Intracellular Accumulation of Amyloid-β (Aβ) Protein Plays a Major Role in Aβ-Induced Alterations of Glutamatergic Synaptic Transmission and Plasticity , 2014, The Journal of Neuroscience.

[3]  Sadegh Nabavi,et al.  Engineering a memory with LTD and LTP , 2014, Nature.

[4]  P. Mecocci,et al.  Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.

[5]  F. Tagliavini,et al.  Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features , 2014, Neurobiology of Aging.

[6]  K. Fox,et al.  The role of nitric oxide in pre-synaptic plasticity and homeostasis , 2013, Front. Cell. Neurosci..

[7]  G. Bitan,et al.  Effects of different amyloid β-protein analogues on synaptic function , 2013, Neurobiology of Aging.

[8]  Shaomin Li,et al.  Environmental Novelty Activates β2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by Aβ Oligomers , 2013, Neuron.

[9]  D. Wicher.  Sensory receptors—design principles revisited , 2013, Front. Cell. Neurosci..

[10]  Greg D. Gale,et al.  Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers. , 2012, Brain : a journal of neurology.

[11]  O. Arancio,et al.  Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. , 2012, Journal of medicinal chemistry.

[12]  I. Hamley.  The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. , 2012, Chemical reviews.

[13]  J. Lehmann,et al.  Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. , 2012, Journal of medicinal chemistry.

[14]  O. Arancio,et al.  Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents. , 2012, Journal of medicinal chemistry.

[15]  Antonio Bastone,et al.  New mutations in MAPT gene causing frontotemporal lobar degeneration: biochemical and structural characterization , 2012, Neurobiology of Aging.

[16]  Antonella Riccio,et al.  A role for neuronal cAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction , 2011, Proceedings of the National Academy of Sciences.

[17]  C. Ghelardini,et al.  Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties. , 2011, Journal of medicinal chemistry.

[18]  Elisabetta Marini,et al.  New nitric oxide or hydrogen sulfide releasing aspirins. , 2011, Journal of medicinal chemistry.

[19]  B. Rolando,et al.  Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. , 2011, ACS medicinal chemistry letters.

[20]  A. Palmer,et al.  Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. , 2011, Trends in pharmacological sciences.

[21]  G. Bitan,et al.  Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone. , 2011, The Biochemical journal.

[22]  Roberto Malinow,et al.  Alzheimer's disease: Recollection of lost memories , 2011, Nature.

[23]  A. V. Santhanam,et al.  Endothelial Nitric Oxide Modulates Expression and Processing of Amyloid Precursor Protein , 2010, Circulation research.

[24]  A. Palamara,et al.  APP Processing Induced by Herpes Simplex Virus Type 1 (HSV-1) Yields Several APP Fragments in Human and Rat Neuronal Cells , 2010, PloS one.

[25]  J. Kuret,et al.  Disaggregation of tau as a therapeutic approach to tauopathies. , 2010, Current Alzheimer research.

[26]  O. Arancio,et al.  Reversal of long-term dendritic spine alterations in Alzheimer disease models , 2009, Proceedings of the National Academy of Sciences.

[27]  J. Kuret,et al.  Structure-activity relationship of cyanine tau aggregation inhibitors. , 2009, Journal of medicinal chemistry.

[28]  E. Mandelkow,et al.  Development of tau aggregation inhibitors for Alzheimer's disease. , 2009, Angewandte Chemie.

[29]  C. Grassi,et al.  Role of methionine 35 in the intracellular Ca2+ homeostasis dysregulation and Ca2+‐dependent apoptosis induced by amyloid β‐peptide in human neuroblastoma IMR32 cells , 2008, Journal of neurochemistry.

[30]  E. Sotelo,et al.  Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of Abeta1-40 aggregation in vitro. , 2008, Bioorganic & medicinal chemistry.

[31]  P. Tosco,et al.  Multitarget drugs: Focus on the NO-donor hybrid drugs , 2008 .

[32]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[33]  V. Subramaniam,et al.  Cyanine dye-protein interactions: looking for fluorescent probes for amyloid structures. , 2007, Journal of biochemical and biophysical methods.

[34]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[35]  Xiongwei Zhu,et al.  Involvement of Oxidative Stress in Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.

[36]  J. Reynolds,et al.  NO chimeras as therapeutic agents in Alzheimer's disease. , 2006, Current Alzheimer research.

[37]  S. Moncada,et al.  The discovery of nitric oxide and its role in vascular biology , 2006, British journal of pharmacology.

[38]  A. Gasco,et al.  The NO‐Releasing Heterocycles , 2005 .

[39]  J. Reynolds,et al.  Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. , 2005, Current Alzheimer research.

[40]  S. Balasubramanian,et al.  Solid-phase methods for the synthesis of cyanine dyes. , 2005, The Journal of organic chemistry.

[41]  Takeshi Iwatsubo,et al.  Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* , 2005, Journal of Biological Chemistry.

[42]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[43]  J. Esplugues.  NO as a signalling molecule in the nervous system , 2002, British journal of pharmacology.

[44]  C. Cena,et al.  New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. , 1998, Journal of medicinal chemistry.

[45]  R. Fruttero,et al.  Unsymmetrically substituted furoxans. Part 16 . Reaction of benzenesulfonyl substituted furoxans with ethanol and ethanethiol in basic medium , 1996 .

[46]  P. Hedera,et al.  Differential degeneration of the cerebral microvasculature in Alzheimer's disease. , 1995, Neuroreport.

[47]  J. Kerwin,et al.  The arginine‐nitric oxide pathway: A target for new drugs , 1994, Medicinal research reviews.

[48]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[49]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[50]  C. Barrow,et al.  Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.

[51]  B. Frangione,et al.  Isolation and Partial Characterization of Neurofibrillary Tangles and Amyloid Plaque Core in Alzheimer's Disease: Immunohistological Studies , 1986, Journal of neuropathology and experimental neurology.

[52]  A. Gasco,et al.  Antimicrobial properties of some furazan and furoxan derivatives. , 1981 .

[53]  H. Puchtler,et al.  ON THE BINDING OF CONGO RED BY AMYLOID , 1962 .

[54]  C. Soto,et al.  Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment , 2007 .

[55]  J. Luvalle,et al.  Synthesis of Very Pure Cyanine Dyes. Preparation of Vinylogous Series of Bis-Thiazolyl, Bis-Thiazolinyl, Bis-Benzothiazolyl, and Bis-Benzoselenazolyl Cyanine lodides. , 1965 .

[56]  W. V. Farrar.  176. The 3,4-bisarenesulphonylfuroxans , 1964 .